### Louisiana Medicaid Colchicine (Lodoco<sup>TM</sup>)

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for colchicine (Lodoco<sup>™</sup>).

Additional Point-of-Sale edits may apply.

By submitting the authorization request, the prescriber attests to the conditions available <u>HERE</u>.

## **Approval Criteria for Initiation of Therapy**

- The recipient is 18 years of age or older on the date of the request; AND
- The recipient has **ONE** of the following:
  - History of myocardial infarction or acute coronary syndrome; **OR**
  - Angina (stable or unstable); **OR**
  - History of stroke or transient ischemic attack; **OR**
  - Coronary artery disease; **OR**
  - Peripheral arterial disease; **OR**
  - History of a coronary or other arterial revascularization procedure; AND
- The medication is being prescribed by, or the request states that this medication is being prescribed in consultation with, a cardiologist; **AND**
- The prescriber **states on the request** that colchicine treatment will be used as an adjunct treatment to the standard of care therapy, which includes, but is not limited to antiplatelet agent, anticoagulant, beta-blocker, lipid-lowering agent, renin-angiotensin inhibitor, etc.

#### **Approval Criteria for Continuation of Therapy**

• The prescriber **states on the request** that the recipient is established on the requested medication and continues to use Lodoco<sup>TM</sup> as an adjunct treatment to the standard of care therapy, which includes, but is not limited to antiplatelet agent, anticoagulant, beta-blocker, lipid-lowering agent, renin-angiotensin inhibitor, etc.

#### Duration of approval for initiation and continuation of therapy: 12 months

#### References

Lodoco (colchicine) [package insert]. Parsippany, NJ: AGEPHA Pharma USA, LLC; June 2023. https://lodoco.com/wp-content/uploads/2023/06/LODOCO\_Prescribing-Information\_6.16.23.pdf

Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2023 Sep 26;148(13):e148] [published correction appears

# in Circulation. 2023 Dec 5;148(23):e186]. Circulation. 2023;148(9):e9-e119. doi:10.1161/CIR.00000000001168

| Revision / Date                | <b>Implementation Date</b> |
|--------------------------------|----------------------------|
| Policy created / November 2024 | March 2025                 |